Staff reviewed
MEDICAID PROGRAM; PROHIBITION ON FEDERAL MEDICAID AND CHILDREN'S HEALTH INSURANCE PROGRAM FUNDING FOR SEX-REJECTING PROCEDURES FURNISHED TO CHILDREN
— STAFF
For publicly insured minors, a nationally binding payer rule now terminates a treatment pathway, and clinicians currently prescribing cross-sex hormones to Medicaid or CHIP beneficiaries have a fixed six-month window in which to plan and counsel around loss of coverage. The reader should expect consequent litigation, state-plan amendments, and capacity-and-consent questions to move from state legislative fights into federal administrative and constitutional channels. The obligation the rule imposes runs to State agencies and their plans rather than to clinicians directly, so this is a systems and access change rather than a change in any evaluator's duty.